Respiratory Muscle Strength in Patients With NMD (RMST)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01555905|
Recruitment Status : Recruiting
First Posted : March 16, 2012
Last Update Posted : January 24, 2019
|Condition or disease||Intervention/treatment||Phase|
|Neuromuscular Disease||Device: Threshold PEP or IMT device Phillips-Respironics||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Respiratory Muscle Strength and Function in Patients With Neuromuscular Disease|
|Study Start Date :||April 2011|
|Estimated Primary Completion Date :||June 2020|
|Estimated Study Completion Date :||December 2020|
Threshold PEP or IMT device Phillips-Respironics
Device: Threshold PEP or IMT device Phillips-Respironics
The subject will be instructed to take 8-15 deep, forceful breaths through the Threshold device, followed by at least 3 minutes of rest. The process will be repeated 3 more times for a total of 4 sets of 8-15 breaths. IMST will be completed three to five days per week, based upon the subject's daily baseline level of fatigue.
- Maximal respiratory pressure [ Time Frame: 3 months ]The primary endpoints for inspiratory muscle training efficacy will be maximal respiratory pressure tests, a measure of respiratory strength.
- Peak flow volumes during loaded breaths [ Time Frame: 3 months ]Secondary outcome measures include respiratory function and breathing pattern during loaded breathing against standard resistances.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01555905
|United States, Florida|
|University of Florida||Recruiting|
|Gainesville, Florida, United States, 32610|
|Contact: Barbara K Smith, PhD, PT 352-294-5315 firstname.lastname@example.org|
|Contact: Lee Kugelmann 352-273-6855 email@example.com|
|Principal Investigator: Barbara K Smith, PhD, PT|
|Principal Investigator:||Barbara K Smith, PhD, PT||University of Florida|